Pro-protein convertases in intermediary metabolism: Islet hormones, brain/gut hormones and integrated physiology

Journal of Molecular Medicine

Volumn 85, Issue 7, 2007, Pages 673-684

  Bataille, Dominique ^a,b  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b CNRS   (France)

Author keywords

Pro protein convertase; Prohormone convertase; Prohormones

Indexed keywords

CARBOXYPEPTIDASE H; CHOLECYSTOKININ; CYCLIC AMP; FURIN; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLICENTIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE TRANSPORTER; HORMONE PRECURSOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INSULIN; INTERMEDIN; LIPOTROPIN; MITOGEN ACTIVATED PROTEIN KINASE; OXYNTOMODULIN; SOMATOSTATIN; SUBTILISIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADIPOCYTE; CARBOXY TERMINAL SEQUENCE; DISULFIDE BOND; FATTY ACID METABOLISM; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HORMONAL REGULATION; HORMONE METABOLISM; INSULIN RELEASE; LANGERHANS CELL; LIPID METABOLISM; NEUROPHYSIOLOGY; NEUROSECRETORY CELL; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN PROCESSING; REVIEW; SECRETORY CELL;

APPETITE REGULATION; BRAIN; HORMONES; HUMANS; INTESTINES; ISLETS OF LANGERHANS; LIPID METABOLISM; PROPROTEIN CONVERTASES; PROTEIN PRECURSORS;

EID: 34447325119     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-007-0167-4     Document Type: Review

References (122)

1. Chrétien M, Li CH (1967) Isolation, purification, and characterization of gamma-lipotropic hormone from sheep pituitary glands. Can J Biochem 45:1163-1174
2. Chrétien M, Benjannet S, Gossard F, Gianoulakis C, Crine P, Lis M, Seidah NG (1979) From beta-lipotropin to beta-endorphin and 'pro-opio-melanocortin'. Can J Biochem 57:1111-1121 (Review)
3. Chrétien M, Gasper L, Benjannet S, Mbikay M, Lazure C, Seidah NG (1990) The Jeremiah Metzger lecture. From POMC to functional diversity of neural peptides: the key importance of convertases. Trans Am Clin Climatol Assoc 102:195-224 (Review)
4. Steiner DF, Cunningham D, Spigelman L, Aten B (1967) Insulin biosynthesis: evidence for a precursor. Science 157:697-700
5. Seidah NG, Day R, Marcinkiewicz M, Chrétien M (1998) Precursor convertases: an evolutionary ancient, cell-specific, combinatorial mechanism yielding diverse bioactive peptides and proteins. Ann NY Acad Sci 839:9-24
6. Steiner DF (1998) The proprotein convertases. Curr Opin Chem Biol 2:31-39
7. Grodsky GM (2000) Kinetics of insulin secretion: underlying metabolic events in diabetes mellitus. In: LeRoith D, Taylor SI, Olefsky JM (eds) Diabetes mellitus. Lippincott Williams & Wilkins, Philadelphia, pp 2-19
8. Steiner DF (2004) The proinsulin C-peptide-a multirole model. Exp Diabesity Res 5:7-14
9. Luzi L, Zerbini G, Caumo A (2007) C-peptide: a redundant relative of insulin? Diabetologia 50:500-502
10. Bataille D (1996) Preproglucagon and its processing. In: Lefèbvre PJ (ed) Glucagon III, handbook of experimental pharmacology. Springer, Berlin Heidelberg New York, pp 31-51
11. Bataille D (1996) Oxyntomodulin and its related peptides. In: Lefèbvre PJ (ed) Glucagon III, handbook of experimental pharmacology. Springer, Berlin Heidelberg New York, pp 327-340
12. Bataille D, Dalle S, Fontés G (2002) Glucagon and miniglucagon: the "mother" and the "enfant terrible" in the metabolic control. Av Diabetol 18:117-120
13. Sherwood NM, Krueckl SL, McRory JE (2000) The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP) / glucagon superfamily. Endocr Rev 21:619-670
14. Rouillé Y, Westermark G, Martin SK, Steiner DF (1994) Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells. Proc Natl Acad Sci USA 91:3242-3246
15. Furuta M, Yano H, Zhou A, Rouillé Y, Holst JJ, Carroll R, Ravazzola M, Orci L, Furuta H, Steiner DF (1997) Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci USA 94:6646-6651
16. Webb GC, Dey A, Wang J, Stein J, Milewski M, Steiner DF (2004) Altered proglucagon processing in an alpha-cell line derived from prohormone convertase 2 null mouse islets. J Biol Chem 279:31068-31075
17. Rothenberg ME, Eilertson CD, Klein K, Zhou Y, Lindberg I, McDonald JK, Mackin RB, Noe BD (1995) Processing of mouse proglucagon by recombinant prohormone convertase 1 and immunopurified prohormone convertase 2 in vitro. J Biol Chem 270:10136-10146
18. Dhanvantari S, Seidah NG, Brubaker PL (1996) Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol 10:342-355
19. + pathway. J Biol Chem 274:10869-10876
20. Dalle S, Fontés G, Lajoix A-D, Le Brigand L, Gross R, Ribes G, Dufour M, Barry L, Le-Nguyen D, Bataille D (2002) Miniglucagon (glucagon 19-29): a novel regulator of the pancreatic islet physiology. Diabetes 51:406-412
21. Fontés G, Lajoix A-D, Bergeron F, Cadel S, Prat A, Foulon T, Gross R, Dalle S, Le-Nguyen D, Tribillac F, Bataille D (2005) Miniglucagon-generating endopeptidase, which processes glucagon into miniglucagon, is composed of NRD-convertase and aminopeptidase-B. Endocrinology 146:702-712
22. Chesneau V, Pierotti AR, Prat A, Gaudoux F, Foulon T, Cohen P (1994) N-arginine dibasic convertase (NRD convertase): a newcomer to the family of processing endopeptidases. An overview. Biochimie 76:234-240
23. Cadel S, Foulon T, Viron A, Balogh A, Midol-Monet S, Noel N, Cohen P (1997) Aminopeptidase B from the rat testis is a bifunctional enzyme structurally related to leukotriene-A4 hydrolase. Proc Natl Acad Sci USA 94:2963-2968
24. Orci L, Malaisse-Lagae F, Ravazzola M, Rouiller D, Renold AE, Perrelet A, Unger RA (1975) morphological basis for intercellular communication between alpha- and beta-cells in the endocrine pancreas. J Clin Invest 56:1066-1070
25. Orci L, Malaisse-Lagae F, Amherdt M, Ravazzola M, Weisswange A, Dobbs R, Perrelet A, Unger R (1975) Cell contacts in human islets of Langerhans. J Clin Endocrinol Metab 41:841-844
26. Samols E, Weir GC, Bonner-Weir S (1983) Intraislet insulin-glucagon- somatostatin relationships. In: Lefèbvre PJ (ed) Glucagon II handbook of experimental pharmacology. Springer, Berlin Heidelberg New York 66/2:133-173
27. Prasadan K, Daume E, Preuett B, Spilde T, Bhatia A, Kobayashi H, Hembree M, Manna P, Gittes GK (2002) Glucagon is required for early insulin-positive differentiation in the developing mouse pancreas. Diabetes 51:3229-3236
28. Samols E (1983) Glucagon and insulin secretion. In: Lefèbvre PJ (ed) Glucagon I, handbook of experimental pharmacology. Springer, Berlin Heidelberg New York, pp 485-518
29. Kawai K, Yokota C, Ohashi S, Watanabe Y, Yamashita K (1995) Evidence that glucagon stimulates insulin secretion through its own receptor in rats. Diabetologia 38: 274-276
30. Huypens P, Ling Z, Pipeleers D, Schuit F (2000) Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 43:1012-1019
31. Moens K, Berger V, Ahn JM, Van Schravenduk C, Hruby VJ, Pipeleers D, Schuit F (2002) Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic beta-cells. Diabetes 51:669-675
32. Dalle S, Longuet C, Costes S, Broca C, Faruque O, Fontés G, Hani E-H, Bataille D (2004) Glucagon promotes CREB phosphorylation via activation of ERK1/2 (extracellular signal-related kinase 1/2) in MIN6 cell line and isolated islets of Langerhans. J Biol Chem 279:20345-20355
33. Dubrasquet M, Bataille D, Gespach C (1982) Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): a potent inhibitor of pentagastrin-stimulated acid secretion in rat. Biosci Rep 2:391-395
34. Jarrousse C, Carles-Bonnet C, Niel H, Sabatier R, Audousset-Puech M-P, Blache P, Kervran A, Martinez J, Bataille D. (1993) Inhibition of gastric acid secretion by oxyntomodulin and its 19-37 fragment in the conscious rat. Am J Physiol 264 (Gastrointest Liver Physiol 27):G816-G823
35. Kirkegaard P, Moody AJ, Holst JJ, Loud FB, Olsen PS, Christiansen J (1982) Glicentin inhibits gastric acid secretion in the rat. Nature 297:156-157
36. Anini Y, Jarrousse C, Chariot J, Nagain C, Yanaihara N, Sasaki K, Bernad N, Le Nguyen D, Bataille D, Rozé C (2000) Oxyntomodulin inhibits pancreatic secretion through the nervous system in rats. Pancreas 20:348-360
37. Beauclair F, Eto B, Pansu D, Rodier G, Mochizuki T, Martinez J, Bataille D, Jarrousse C (1998) Oxyntomodulin reduces hydromineral transport through rat small intestine. Dig Dis Sci 43:1814-1823
38. Hirotani Y, Taki M, Kataoka K, Kurokawa N, Satoh T, Sasaki K, Yanaihara C, Luo WQ, Yanaihara N (1998) Effect of rat glicentin on intestinal adaptation in small intestine-resected rats. Ann NY Acad Sci 865:601-605
39. Pelissier S, Sasaki K, Le-Nguyen D, Bataille D, Jarrousse C (2004) Oxyntomodulin and glicentin are potent inhibitors of the fed motor pattern in the rat small intestine. Neurogastroenterol Motil 16: 455-463
40. Rodier G, Magous R, Mochizuki T, Le Nguyen D, Martinez J, Bali JP, Bataille D, Jarrousse C (1999) Glicentin and oxyntomodulin modulate both the phosphoinositide and cyclic adenosine monophosphate signaling pathways in gastric myocytes. Endocrinology 140:22-28
41. Meier JJ, Nauck MA (2005) Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev 21:91-117
42. Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3:153-165
43. Drucker DJ (2001) Glucagon-like peptide 2. J Clin Endocrinol Metab 86:1759-1764
44. Le Quellec A, Kervran A, Blache P, Ciurana A, Bataille D (1992) Oxyntomodulin-like immunoreactivity: Diurnal profile of a new potential enterogastrone. J Clin Endocrinol Metab 74:1405-1409
45. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B (1995) Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56:117-126
46. Plaisancié P, Dumoulin V, Chayvialle JA, Cuber JC (1995) Luminal glucagon-like peptide-1(7-36) amide-releasing factors in the isolated vascularly perfused rat colon. J Endocrinol 145:521-526
47. Damholt AB, Kofod H, Buchan AM (1999) Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine. Cell Tissue Res 1999 298:287-293
48. Hansen L, Holst JJ (2002) The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno-ileal loop? Regul Pept 110:39-45
49. Brown JC, Dryburgh JR (1971). A gastric inhibitory polypeptide. II. The complete amino acid sequence. Can J Biochem 49:867-872
50. Pederson RA, Brown JC (1976). The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 99:780-785
51. Dupré J, Ross SA, Watson D, Brown JC (1973) Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37:826-828
52. Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, Egan JM (2006) Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 290:E550-E559
53. Tseng C-C, Jarboe LA, Landau SB, Williams EK, Wolfe M (1993) Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat. Proc Natl Acad Sci USA 90:1992-1996
54. Ugleholdt R, Poulsen ML, Holst PJ, Irminger JC, Ørskov C, Pedersen J, Rosenkilde MM, Zhu X, Steiner DF, Holst JJ (2006). Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor. J Biol Chem 281:11050-11070
55. Xie L, Lu J, Ostenson CG, Xu T, Chen ZW (2004) GIP(1-39), a novel insulinotropic peptide form and aspects on its mechanism of action. Regul Pept 121:107-112
56. Gault VA, Parker JC, Harriott P, Flatt PR, O'Harte FP (2002) Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol 175:525-533
57. Pradayrol L, Jörnvall H, Mutt V, Ribet A (1980) N-terminally extended somatostatin: the primary structure of somatostatin-28. FEBS Lett 109:55-58
58. Brakch N, Galanopoulou AS, Patel YC, Boileau G, Seidah NG (1995) Comparative proteolytic processing of rat prosomatostatin by the convertases PC1, PC2, furin, PACE4 and PC5 in constitutive and regulated secretory pathways. FEBS Lett 362:143-146
59. Galanopoulou AS, Seidah NG, Patel YC (1995) Heterologous processing of rat prosomatostatin to somatostatin-14 by PC2: requirement for secretory cell but not the secretion granule. Biochem J 311:111-118
60. Winsky-Sommerer R, Grouselle D, Rougeot C, Laurent V, David JP, Delacourte A, Dournaud P, Seidah NG, Lindberg I, Trottier S, Epelbaum J (2003) The proprotein convertase PC2 is involved in the maturation of prosomatostatin to somatostatin-14 but not in the somatostatin deficit in Alzheimer's disease. Neuroscience 122:437-447
61. Miller R, Toneff T, Vishnuvardhan D, Beinfeld M, Hook VY (2003) Selective roles for the PC2 processing enzyme in the regulation of peptide neurotransmitter levels in brain and peripheral neuroendocrine tissues of PC2 deficient mice. Neuropeptides 37:140-148
62. Gluschankof P, Gomez S, Morel A, Cohen P (1987) Enzymes that process somatostatin precursors. A novel endoprotease that cleaves before the arginine-lysine doublet is involved in somatostatin-28 convertase activity of rat brain cortex. J Biol Chem 262:9615-9620
63. Patel YC, Galanopoulou AS, Rabbani SN, Liu JL, Ravazzola M, Amherdt M (1997) Somatostatin-14, somatostatin-28, and prosomatostatin1-10 are independently and efficiently processed from prosomatostatin in the constitutive secretory pathway in islet somatostatin tumor cells (1027B2). Mol Cell Endocrinol 131:183-194
64. Patel YC, Galanopoulou A (1995) Processing and intracellular targeting of prosomatostatin-derived peptides: the role of mammalian endoproteases. Ciba Found Symp 190:26-40
65. Brakch N, Lazar N, Panchal M, Allemandou F, Boileau G, Cohen P, Rholam M (2002) The somatostatin-28(1-12)-NPAMAP sequence: an essential helical-promoting motif governing prosomatostatin processing at mono- and dibasic sites. Biochemistry 41:1630-1639
66. Mouchantaf R, Watt HL, Sulea T, Seidah NG, Alturaihi H, Patel YC, Kumar U (2004) Prosomatostatin is proteolytically processed at the amino terminal segment by subtilase SKI-1. Regul Pept 120:133-140
67. Vaysse N, Pradayrol L, Chayvialle JA, Pignal F, Esteve JP, Susini C, Descos F, Ribet A (1981) Effects of somatostatin-14 and somatostatin-28 on bombesin-stimulated release of gastrin, insulin, and glucagon in the dog. Endocrinology 108:1843-1847
68. Esteve JP, Vaysse N, Susini C, Kunsch JM, Fourmy D, Pradayrol L, Wünsch E, Moroder L, Ribet A (1983) Bimodal regulation of pancreatic exocrine function in vitro by somatostatin-28. Am J Physiol 245:G208-G216
69. Funaki M, Randhawa P, Janmey PA (2004) Separation of insulin signaling into distinct GLUT4 translocation and activation steps. Mol Cell Biol 24:7567-7577
70. Zunz E, La Barre J. (1929) Contributions à l'étude des variations physiologiques de la sécrétion interne du pancreas. Relations entre les sécrétions externe et interne du pancréas. Arch Int Physiol Biochim 31:20-44
71. McIntyre N, Holdsworth CD, Turner DS (1965) Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab 2:1317-1324
72. Creutzfeldt W, Nauck M (1992) Gut hormones and diabetes mellitus. Diabetes Metab Rev 8:149-177
73. Elrick H, Stimmler L, Hlad CJ, Arai Y (1964) Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab 24:1076-1082
74. Vilsbøll T, Krarup T, Madsbad S, Holst JJ (2003) Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114:115-121
75. Gault VA, O'Harte FPM, Harriott P, Mooney MH, Green BD, Flatt PR (2003). Effects of the novel (Pro 3)GIP antagonist and exendin(9-39)amide on GIP and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia 46: 222-230
76. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B (2002) Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept 107:1-13
77. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W (1993). Preserved incretin activity of glucagon-like peptide 1 7-36 amide but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307
78. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609-613
79. Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE, Nauck MA (2003) Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46:798-801
80. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Göke B (2006) Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 55:243-251 [comment in Horowitz and Nauck, Gut 55(2):148-150, 2006]
81. Ehses JA, Pelech SL, Pederson RA, McIntosh CHS (2002) Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J Biol Chem 277:37088-37097
82. Holz GG 4th, Kuhtreiber WM, Habener JF (1993) Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 361:362-365
83. Dachicourt N, Serradas P, Bailbe D, Kergaot M, Doare L, Portha B (1997) Glucagon-like peptide-1(7-36)-amide confers glucose sensitivity to previously glucose incompetent beta-cells in diabetic rats: in vivo and in vitro studies. J Endocrinol 155:369-376
84. Bataille D, Fontés G, Costes S, Longuet C, Dalle S (2006) The glucagon/miniglucagon interplay: a new level in the metabolic regulation. Ann NY Acad Sci 1070:161-166
85. Boden G, Chen X (2000) Fatty acids and insulin resistance. In: LeRoith D, Taylor SI, Olefsky JM (eds) Diabetes mellitus. Lippincott Williams & Wilkins, pp 659-663
86. Lefèbvre PJ (1983) Glucagon and adipose tissue lipolysis. In: Lefèbvre PJ (ed) Glucagon I, handbook of experimental pharmacology. Springer, Heidelberg, 99/1 pp 419-440
87. Valverde I, Morales M, Clemente F, Lopez-Delgado MI, Delgado E, Perea A et al (1994) Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett 349:313-316
88. Valverde I, Villanueva-Penacarrillo ML, Malaisse WJ (2002) Pancreatic and extrapancreatic effects of GLP-1. Diabetes Metab 28: 3S85-3S89; discussion 3S108-3S112
89. Ikezawa Y, Yamatani K, Ohnuma H, Daimon M, Manaka H, Sasaki H (2003) Glucagon-like peptide-1 inhibits glucagon-induced glycogenolysis in perivenous hepatocytes specifically. Regul Pept 111:207-210
90. Montrose-Rafizadeh C, Yang H, Wang Y, Roth J, Montrose MH, Adams LG (1997) Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J Cell Physiol 172:275-283
91. Mayo KE, Miller LJ, Bataille D, Dalle S, Göke B, Thorens B, Drucker DJ (2003) International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 55:1-28
92. Morfis M, Christopoulos A, Sexton PM (2003) RAMPs: 5 years on, where to now? Trends Pharmacol Sci 24:596-601
93. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G (1997) Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 100:1166-1173
94. Kieffer TJ (2003) GIP or not GIP? that is the question. TIPS 24:110-112
95. Friedman JM (2004) Modern science versus the stigma of obesity. Nat Med 10: 563-569
96. Druce M, Bloom SR (2003) Central regulators of food intake. Curr Opin Clin Nutr Metab Care 6:361-367
97. Merchenthaler I (1991) Neurons with access to the general circulation in the central nervous system of the rat: a retrograde tracing study with fluoro-gold. Neuroscience 44:655-662
98. Cone RD, Cowley MA, Butler AA, Fan W, Marks DL, Low MJ (2001) The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 25 Suppl 5:S63-S67
99. Gualilloa O, Lagob F, Gomez-Reino J, Casanueva FF, Dieguez C (2003) Ghrelin, a widespread hormone: insights into molecular and cellular regulation of its expression and mechanism of action. FEBS Lett 552:105-109
100. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50:1714-1719
101. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, Batterham RL, Taheri S, Stanley SA, Ghatei MA, Bloom SR (2001) Ghrelin causes hyperphagia and obesity in rats. Diabetes 50:2540-2547
102. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin, DG (2000) Central nervous system control of food intake. Nature 404:661-671
103. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418:650-654
104. Tschöp M, Castañeda TR, Joost HG, Thöne-Reineke C, Ortmann S et al (2004) Does gut hormone PYY3-36 decrease food intake in rodents ? Nature 430 (6996):p1
105. Nauck, MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, Schmiegel WH (1997) Glucagon like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273 (Endocrinol Metab 36):E981-E988
106. Tang-Christensen M, Larsen PJ, Göke R, Fink-Jensen A, Jessop DS, Moller M, Sheikh SP (1996) Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271:R848-R856
107. Meeran K, O'Shea D, Edwards CM et al (1999) Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140:244-250
108. Rodriquez de Fonseca F, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O, Gomez R, Munoz RM, Eng J, Blazquez E (2000) Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49:709-717
109. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25:781-792
110. Schick RR, Zimmermann JP, Vorm Walde T, Schusdziarra V (2003) Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats. Am J Physiol Regul Integr Comp Physiol 284: R1427-R1435
111. Turton MD, O'Shea D, Gunn I et al (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72
112. Serre V, Dolci W, Schaerer E, Scrocchi L, Drucker D, Efrat S, Thorens B (1998) Exendin (9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′,5′monophosphate levels and β-cell glucose competence. Endocrinology 139:4448-4454
113. Gutzwiller JP, Drewe J, Göke B et al (1999) Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276:R1541-R1544
114. Toft-Nielsen MB, Madsbad S, Holst JJ (1999) Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137-1143
115. Naslund E, Barkeling B, King N et al (1999) Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23:304-311
116. Verdich C, Flint A, Gutzwiller JP et al (2001) A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86:4382-4389
117. Long SJ, Sutton JA, Amaee WB et al (1999) No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man. Br J Nutr 81:273-279
118. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, Ghatei MA, Bloom SR (2001) Oxyntomodulin inhibits food intake in the rat. Endocrinology142:4244-4250
119. Dakin CL, Small CJ, Park AJ, Seth A, Ghatei MA, Bloom SR (2002) Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 283:E1173-E1177
120. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, Bloom SR (2004) Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145:2687-2695
121. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, Bloom SR (2003) Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88:4696-4701
122. Baggio LL, Huang Q, Brown TJ, Drucker DJ (2004) Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127:546-558